Skip to content

Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjdementia
VJNeurology
Logo
  • Home (current)
  • Diseases
    Parkinson's Disease
    Multiple Sclerosis and Related Disorders
    Headache
    Amyotrophic Lateral Sclerosis
    Epilepsy
    Sleep Disorders
    Stroke
    Neuromuscular Disorders
    Movement Disorders
    View all Diseases
  • Topics
    Biology
    Diagnostics
    Trial Updates
    Treatment
    Prevention
    Surgery
    Imaging
    Genetics
    COVID-19
    View all Topics
  • Conferences
    AAN 2023
    BNA 2023
    AD/PD 2023
    CONy 2023
    ACTRIMS 2023
    ISC 2023
    View all Conferences
  • Features
  • Podcasts
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

William E. Rosenfeld

How will the role of cenobamate evolve in the epilepsy space? 5:36
How will the role of cenobamate evolve in the epilepsy space?
William E. Rosenfeld • 12 Dec 2022
SUDEP rates in the cenobamate development program 7:19
SUDEP rates in the cenobamate development program
William E. Rosenfeld • 12 Dec 2022
Cenobamate therapy reduces concomitant drug load in patients with epilepsy 2:23
Cenobamate therapy reduces concomitant drug load in patients with epilepsy
William E. Rosenfeld • 12 Dec 2022
Early and sustained responses to cenobamate across focal seizure subtypes 7:01
Early and sustained responses to cenobamate across focal seizure subtypes
William E. Rosenfeld • 4 Apr 2022
Cenobamate for focal seizures: longer-term efficacy and adverse events 2:55
Cenobamate for focal seizures: longer-term efficacy and adverse events
William E. Rosenfeld • 4 Apr 2022
Cenobamate plasma concentrations in 50% and 100% responders 4:47
Cenobamate plasma concentrations in 50% and 100% responders
William E. Rosenfeld • 4 Apr 2022
How to manage patients receiving adjunctive cenobamate 7:02
How to manage patients receiving adjunctive cenobamate
William E. Rosenfeld • 4 Apr 2022
Cognitive and psychiatric adverse events associated with cenobamate 2:38
Cognitive and psychiatric adverse events associated with cenobamate
William E. Rosenfeld • 4 Apr 2022
Journal Pages
  • Diseases
  • Topics
  • Medicines
  • Trials
  • Conferences
  • Features
Newsletter

Receive the latest news and videos from VJNeurology via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJNeurology logo
The content of VJNeurology is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy